多肽探针在肿瘤成像中的研究进展

doi:10.11904/j.issn.1002-3070.2022.04.013

摘要/Abstract

摘要： 肿瘤的精准成像在识别肿瘤位置和分期以及确定合适的治疗方法方面发挥着重要作用。多肽是在成像方面具有前途的工具,已证明相应的受体在肿瘤细胞中过表达,通过与受体特异性结合导致显像剂在肿瘤细胞内成像。此外,由于多肽具有分子量小、免疫原性低、亲和力和特异性高等众多优点使其在肿瘤诊断和治疗中受到越来越多的关注,一些基于多肽的成像探针和治疗剂已成功进入临床试验。本文就多肽探针在肿瘤成像中的研究进展进行综述。

关键词: 多肽探针, 肿瘤, 成像诊断

Abstract: Accurate imaging of tumors plays an important role in identifying tumor location and staging,and determining the appropriate treatment methods.Peptides are promising tools in imaging,and the corresponding receptors have been shown to be overexpressed in tumor cells,leading to imaging agents within tumor cells by specifically binding to the receptors.In addition,peptides have attracted more and more attention in tumor diagnosis and treatment due to their small molecular weight,low immunogenicity,high affinity and specificity,and some peptide-based imaging probes and therapeutic agents have successfully entered clinical trials.This article reviews the research progress of peptide probes in tumor imaging.

Key words: Peptides probe, Tumor, Imaging diagnosis

中图分类号:

R730

郭玲, 苏亚娟. 多肽探针在肿瘤成像中的研究进展[J]. 实用肿瘤学杂志, 2022, 36(4): 360-363.

GUO Ling, SU Yajuan. Research progress of peptide probe in tumor imaging[J]. Journal of Practical Oncology, 2022, 36(4): 360-363.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2022.04.013

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2022/V36/I4/360

参考文献

1 Fan X,Xu H,Song J,et al.Using a membrane-penetrating-peptide to anchor ligands in the liposome membrane facilitates targeted drug delivery[J].Bioconjug Chem,2020,31(1):113-122.
2 黎玉娇,尚乃舰.影像学评估乳腺癌新辅助化疗反应的研究进展[J].实用肿瘤学杂志,2018,153(1):63-67.
3 Hossein-Nejad-Ariani H,Althagafi E,Kaur K,et al.Small peptide ligands for targeting EGFR in triple negative breast cancer cells[J].Sci Rep,2019,9(1):2723.
4 Flatmark K,Torgunrud A,Fleten KG,et al.Peptide vaccine targeting mutated GNAS:a potential novel treatment for pseudomyxoma peritonei[J].J Immunother Cancer,2021,9(10):3109.
5 Vadevoo SMP,Gurung S,Khan F,et al.Peptide-based targeted therapeutics and apoptosis imaging probes for cancer therapy[J].Arch Pharm Res,2019,42(2):150-158.
6 Zhao N,Qin Y,Liu H,et al.Tumor-Targeting Peptides:ligands for molecular imaging and therapy[J].Anticancer Agents Med Chem,2018,18(1):74-86.
7 Wang W,Hu Z.Targeting Peptide-based probes for molecular imaging and diagnosis[J].Adv Mater,2019,31(45):1804827.
8 Cardle II,Jensen MC,Pun SH,et al.Optimized serum stability and specificity of an αvβ6 integrin-binding peptide for tumor targeting[J].J Biol Chem,2021,296:100657.
9 Ramezanizadeh M,Masterifarahani A,Sadeghzadeh N,et al.99mTc-D(RGD):molecular imaging probe for diagnosis of αvβ3-positive tumors[J].Nucl Med Commun,2020,41(2):104-109.
10 Zhang Y,Wang L,Yu S,et al.Synthesis and preclinical evaluation of the fibrin-binding cyclic peptide ¹⁸F-iCREKA:comparison with its contrasted linear peptide[J].Contrast Media Mol Imaging,2019,2019:6315954.
11 Liolios C,Sachpekidis C,Kolocouris A,et al.PET Diagnostic molecules utilizing multimeric cyclic RGD peptide analogs for imaging integrin αvβ3 receptors[J].Molecules,2021,26(6):1792.
12 Xiong J,Yan L,Zou C,et al.Integrins regulate stemness in solid tumor:an emerging therapeutic target[J].J Hematol Oncol,2021,14(1):177.
13 Karamzade-Ziarati N,Manafi-Farid R,Ataeinia B,et al.Molecular imaging of bone metastases using tumor-targeted tracers[J].Q J Nucl Med Mol Imaging,2019,63(2):136-149.
14 Beer AJ,Haubner R,Goebel M,et al.Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer ¹⁸F-galacto-RGD in cancer patients[J].J Nucl Med,2005,46(8):1333-1341.
15 Beer AJ,Niemeyer M,Carlsen J,et al.Patterns of alphavbeta3 expression in primary and metastatic human breast cancer as shown by ¹⁸F-Galacto-RGD PET[J].J Nucl Med,2008,49(2):255-259.
16 Beer AJ,Lorenzen S,Metz S,et al.Comparison of integrin alphaVbeta3 expression and glucose metabolism in primary and metastatic lesions in cancer patients:a PET study using ¹⁸F-galacto-RGD and ¹⁸F-FDG[J].J Nucl Med,2008,49(1):22-29.
17 Florea A,Mottaghy FM,Bauwens M.Molecular imaging of angiogenesis in oncology:current preclinical and clinical status[J].Int J Mol Sci,2021,22(11):5544.
18 Minamimoto R,Jamali M,Barkhodari A,et al.Biodistribution of the ¹⁸F-FPPRGD₂ PET radiopharmaceutical in cancer patients:an atlas of SUV measurements[J].Eur J Nucl Med Mol Imaging,2015,42(12):1850-1858.
19 Iagaru A,Mosci C,Shen B,et al.(18)F-FPPRGD2 PET/CT:pilot phase evaluation of breast cancer patients[J].Radiology,2014,273(2):549-559.
20 Liu Y,Xu C,Liu HW,et al.Precipitated fluorophore-based molecular probe for in situ imaging of aminopeptidase N in living cells and tumors[J].Anal Chem,2021,93(16):6463-6471.
21 Kis A,Dénes N,Szabó JP,et al.In vivo assessment of aminopeptidase N(APN/CD13)specificity of different ⁶⁸Ga-labelled NGR derivatives using PET/MRI imaging[J].Int J Pharm,2020,589:119881.
22 Israel I,Elflein K,Schirbel A,et al.A comparison of the monomeric[⁶⁸Ga]NODAGA-NGR and dimeric[⁶⁸Ga]NOTA-(NGR)2 as aminopeptidase N ligand for positron emission tomography imaging in tumor-bearing mice[J].Eur J Pharm Sci,2021,166:105964.
23 Yang Y,Zhang J,Zou H,et al.Synthesis and evaluation of ⁶⁸Ga-labeled dimeric cNGR peptide for PET imaging of CD13 expression with ovarian cancer xenograft[J].J Cancer,2021,12(1):244-252.
24 Zhu L,Ding Z,Li X,et al.Research progress of radiolabeled Asn-Gly-Arg(NGR)peptides for Imaging and therapy[J].Mol Imaging,2020,19:1536012120934957.
25 Baratto L,Duan H,Mäcke H,et al.Imaging the distribution of gastrin-releasing peptide receptors in cancer[J].J Nucl Med,2020,61(6):792-798.
26 Touijer KA,Michaud L,Alvarez HAV,et al.Prospective study of the radiolabeled GRPR antagonist BAY86-7548 for positron emission tomography/computed tomography imaging of newly diagnosed prostate cancer[J].Eur Urol Oncol,2019,2(2):166-173.
27 Wieser G,Popp I,Christian Rischke H,et al.Diagnosis of recurrent prostate cancer with PET/CT imaging using the gastrin-releasing peptide receptor antagonist ⁶⁸Ga-RM2:Preliminary results in patients with negative or inconclusive [18F] Fluoroethylcholine-PET/CT[J].Eur J Nucl Med Mol Imaging,2017,44(9):1463-1472.
28 Minamimoto R,Hancock S,Schneider B,et al.Pilot comparison of ⁶⁸Ga-RM2 PET and ⁶⁸Ga-PSMA-11 PET in patients with biochemically recurrent prostate cancer[J].J Nucl Med,2016,57(4):557-562.
29 He K,Chi C,Li D,et al.Resection and survival data from a clinical trial of glioblastoma multiforme-specific IRDye800-BBN fluorescence-guided surgery[J].Bioeng Transl Med,2020,6(1):10182.
30 Hu Y,Ye Z,Wang F,et al.Role of somatostatin receptor in pancreatic neuroendocrine tumor development,diagnosis,and therapy[J].Front Endocrinol(Lausanne),2021,12:679000.
31 Zhang L,Vines DC,Scollard DA,et al.Correlation of somatostatin receptor-2 expression with Gallium-68-DOTA-TATE Uptake in neuroblastoma xenograft models[J].Contrast Media Mol Imaging,2017,2017:9481276.
32 Sadowski SM,Neychev V,Millo C,et al.Prospective study of ⁶⁸Ga-DOTATATE positron emission tomography/computed tomography for detecting gastro-entero-pancreatic neuroendocrine tumors and unknown primary sites[J].J Clin Oncol,2016,34(6):588-596.
33 Xie Q,Liu T,Ding J,et al.Synthesis,preclinical evaluation,and a pilot clinical imaging study of [18F] AlF-NOTA-JR11 for neuroendocrine neoplasms compared with[⁶⁸Ga]Ga-DOTA-TATE[J].Eur J Nucl Med Mol Imaging,2021,48(10):3129-3140.

[1]	李鑫林, 周金意, 韩仁强, 蔡波, 徐红, 韩颖颖. 2013—2017年南通市肺癌流行病学特征分析[J]. 实用肿瘤学杂志, 2022, 36(4): 304-309.
[2]	孙伟玲, 张明辉, 吴华星, 赵艳滨. 血清肿瘤标志物对肺癌患者支气管镜活检病理组织学分型的预测价值[J]. 实用肿瘤学杂志, 2022, 36(4): 316-322.
[3]	孙阜圣, 徐冶, 张永健, 娄阁. 卵巢癌类器官模型的研究进展和治疗新策略[J]. 实用肿瘤学杂志, 2022, 36(4): 346-350.
[4]	李原, 张玲. 消化系统肿瘤发生有丝分裂危象的研究进展[J]. 实用肿瘤学杂志, 2022, 36(4): 356-359.
[5]	赵梓楠, 王国年. SOX4在消化系统恶性肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2022, 36(4): 364-368.
[6]	刘欣欣, 姚欣卉, 孙跃峰, 缪美琪, 陈晶. 乳腺癌微环境中趋化因子CCL20作用的研究进展[J]. 实用肿瘤学杂志, 2022, 36(3): 250-254.
[7]	杨楠, 王棹, 张玉, 张云艳. SMYD2在恶性肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2022, 36(3): 273-277.
[8]	王雷雷, 陈辉. T1期高级别尿路上皮癌的治疗进展[J]. 实用肿瘤学杂志, 2022, 36(3): 283-287.
[9]	张宁, 蔺刘亚, 李思繁, 朱萌. miR-106a靶向调控TIMP2对人胃癌细胞增殖、转移及EMT的影响[J]. 实用肿瘤学杂志, 2022, 36(2): 105-110.
[10]	胡宗涛, 刘演, 高世乐, 甘晨, 张永康. 高剂量少分次放疗联合白蛋白结合型紫杉醇、替吉奥方案化疗在局部晚期胰腺癌患者中的临床疗效以及安全性评价[J]. 实用肿瘤学杂志, 2022, 36(2): 144-149.
[11]	吴芳芳, 郑桐森. 胆道恶性肿瘤辅助治疗的研究现状及展望[J]. 实用肿瘤学杂志, 2022, 36(2): 156-161.
[12]	刘雨, 俞星新, 耿志达, 陈政良, 惠鹏, 梁英健. 成纤维细胞在肝癌发生发展中的作用[J]. 实用肿瘤学杂志, 2022, 36(2): 167-172.
[13]	唐菊, 尚利华. BMI与免疫检查点抑制剂治疗恶性肿瘤疗效的关系[J]. 实用肿瘤学杂志, 2022, 36(2): 188-192.
[14]	王艳平, 邱琳, 武萌, 飒日娜. 2016年陕西省恶性肿瘤发病与死亡分析[J]. 实用肿瘤学杂志, 2022, 36(1): 1-6.
[15]	董丽娜, 梁田, 张献, 张广美. 卵巢癌对富脂大网膜的器官趋向性转移的研究进展[J]. 实用肿瘤学杂志, 2022, 36(1): 54-58.